Last reviewed · How we verify
NCT06183762
A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer
trial testing No treatment is included in this protocol. in Advanced Lung Cancer in 200 participants. Currently enrolling.
31 December 2024
Quick facts
| Lead sponsor | Hunan Province Tumor Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 January 2020 |
| Primary completion | 31 December 2024 |
| Estimated completion | 30 June 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- No treatment is included in this protocol.
Conditions studied
- Advanced Lung Cancer — all drugs for Advanced Lung Cancer →
Sponsor
Hunan Province Tumor Hospital
Who can join
18 and older, any sex, with Advanced Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical practice of the enrolled patients. Data will be collected in a forward-looking manner. This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical practice of the enrolled patients. Data from patients on prior treatment will be collected retrospectively, and data from patients who will be treated later and included in the study will be collected in a prospective manner. The criteria for retrospective collection were consistent with those for prospective collection. Eligible patients will be enrolled after NGS analysis of tumor tissue and informed consent has been obtained. Information required for the study will be collected (every 3 months).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Pyrazolopyridine-based kinase inhibitors for anti-cancer targeted therapy.
Halder P, Rai A, Talukdar V, Das P, et al · · 2024 · cited 7× · PMID 38784451 · DOI 10.1039/d4md00003j
Verify or expand the search:
- PubMed search for NCT06183762
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No treatment is included in this protocol.
Trials testing the same drug.
- NCT03605602 — A Real World Study Based on NGS (TRUMPRWS) · unknown
Other recruiting trials for Advanced Lung Cancer
Currently open trials in the same condition.
- NCT07227623 — A Digital Health Intervention to Improve Physical Function and Wellness of Lung Cancer Survivors · NA · recruiting
- NCT06992583 — Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer · Phase 1 · recruiting
- NCT06945523 — Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advan · Phase 1 · recruiting
- NCT06903117 — Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma · Phase 1 · recruiting
- NCT06928922 — Inhaled mRNA Tumor-associated Antigen Dry Powder Vaccine in Advanced Lung Cancer and Lung Metastasis of Solid Tumors. · EARLY_PHASE1 · recruiting
Other Hunan Province Tumor Hospital trials
Trials by the same sponsor.
- NCT06706219 — Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unres · Phase 2 · not yet recruiting
- NCT07001995 — Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression · Phase 2 · not yet recruiting
- NCT07477808 — Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer · Phase 3 · not yet recruiting
- NCT07251582 — Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer · Phase 3 · recruiting
- NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06183762 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hunan Province Tumor Hospital
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06183762.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing